We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Akebia Therapeutics (AKBA - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Akebia Therapeutics is one of 951 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Akebia Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for AKBA's full-year earnings has moved 201.6% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, AKBA has moved about 16.3% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 4.5% on average. This means that Akebia Therapeutics is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Humana (HUM - Free Report) . The stock is up 9.7% year-to-date.
The consensus estimate for Humana's current year EPS has increased 0.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Akebia Therapeutics belongs to the Medical - Drugs industry, a group that includes 144 individual stocks and currently sits at #86 in the Zacks Industry Rank. Stocks in this group have gained about 7.6% so far this year, so AKBA is performing better this group in terms of year-to-date returns.
On the other hand, Humana belongs to the Medical - HMOs industry. This 8-stock industry is currently ranked #180. The industry has moved -28.4% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Akebia Therapeutics and Humana as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Akebia Therapeutics (AKBA - Free Report) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.
Akebia Therapeutics is one of 951 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Akebia Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for AKBA's full-year earnings has moved 201.6% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
According to our latest data, AKBA has moved about 16.3% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 4.5% on average. This means that Akebia Therapeutics is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is Humana (HUM - Free Report) . The stock is up 9.7% year-to-date.
The consensus estimate for Humana's current year EPS has increased 0.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Akebia Therapeutics belongs to the Medical - Drugs industry, a group that includes 144 individual stocks and currently sits at #86 in the Zacks Industry Rank. Stocks in this group have gained about 7.6% so far this year, so AKBA is performing better this group in terms of year-to-date returns.
On the other hand, Humana belongs to the Medical - HMOs industry. This 8-stock industry is currently ranked #180. The industry has moved -28.4% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Akebia Therapeutics and Humana as they could maintain their solid performance.